The Bull Rankings scorecard — our quality-growth score is 40.5 / 100, built from three pillars scored 0–100: Quality 33, Growth 70, Value 28 (valuation is judged against sector peers).
The thesis
Bunge Global is a growth story that doesn’t look cheap. The market has barely blinked at a business that grew revenue 17.5% in the year ended 2026-03-31, much of it from buying Viterra, yet its stock still trades near the midpoint of its 52-week range, as if the growth is a one-off rather than the start of a cycle. Our model’s Growth pillar at 70 is the standout, and the business behind it pairs volume upside in soybeans and softseeds, pricing power in refined oils, and expanding biodiesel margins—all while competitors scramble to match scale. But the Value pillar at 28 tells the other side: a price-to-sales of 1.2 and negative free cash flow of -$1.2 billion over the last twelve months don’t scream discount. The market is pricing in a slow fade, and our model’s Quality score of 33 gives little reason to expect compounding. Either the growth is sustainable and the price is justified, or the cycle turns and the valuation finally catches up.
What the business actually is
Bunge turns raw oilseeds into refined products the world can’t do without. In the Soybean Processing and Refining segment, it buys, stores, and crushes soybeans to produce meal for animal feed, oil for food and biodiesel, and fertilizer co-products. The Softseed Processing and Refining segment does the same for sunflower, canola, and rapeseed, selling oil to food manufacturers and meal to dairy and poultry farms. Smaller but strategic is Other Oilseeds Processing and Refining, which handles niche crops like palm kernel and coconut, and Grain Merchandising and Milling, which moves wheat and corn for flour and ethanol markets. The engine is volume: more acres planted to soybeans and canola mean more crush, more oil to sell at a premium, and more meal to move into feed channels. The biodiesel tailwind—where Bunge supplies soybean oil for renewable diesel—adds a policy-driven kicker that competitors without integrated refining can’t replicate overnight.
Why it can (or can't) keep compounding
The durability hinges on two things: scale in logistics and refining, and policy leverage. Bunge’s global network of elevators, crush plants, and refineries creates a moat that’s hard to breach. A rival can build a crushing plant, but replicating Bunge’s integrated supply chain—from farm gate to biodiesel pump—takes years and billions. The Diluting shareholders signal mostly reflects the shares issued to buy Viterra; it’s a warning, not a death knell, but it erodes per-share returns. Still, return on equity of 4.3% is weak, and profit margins of 3.8% show how thin the business is once you account for working capital and hedging. The growth pillar is strong, but the quality pillar is weak—meaning this isn’t a compounder yet. It’s a growth story with a cash-burn habit.
The valuation question
The market isn’t treating the growth as a bargain. A price-to-sales of 1.2 is rich for a low-margin processor, and it leaves little room if the 17.5% revenue growth in the year ended 2026-03-31 proves to be the peak. Our reverse DCF has no read for Bunge, so the valuation case rests on the multiples. The analyst consensus 1-year target of $141.22 sits 25% above today’s price, but that optimism is fragile. If the growth slows to mid-single digits, the multiple will compress, and the upside disappears. The bull case is that the market is underestimating the staying power of biodiesel margins and the resilience of global feed demand. The bear case is that the multiple is already giving credit for growth that’s about to roll over.
The bear case
The strongest argument against BG is the free cash flow burn of -$1.2 billion over the last twelve months. A business that can’t generate cash while growing revenue is a capital-intensive treadmill, not a compounder. The debt-to-equity of 0.98 means the balance sheet isn’t a crisis yet, but it’s a constraint—every dollar of growth requires more leverage or dilution. If the revenue growth slows or input costs spike, the thin margins will evaporate, and the stock’s beta of 0.65 will look optimistic. The market’s recent whipsaw—where BG outperformed one day and underperformed the next—hints at a stock that’s trading on sentiment, not fundamentals. The moment the volume growth stalls, the valuation will follow.
What would change our mind
Three numbers would flip the thesis. First, free cash flow turning positive—if the TTM figure crosses into positive territory, it signals the growth investments are paying off, not just consuming capital. Second, return on equity climbing above 8%, which would show the business is finally earning a respectable return. Third, revenue growth reaccelerating to 20% or higher in the next reported quarter, proving the 17.5% wasn’t a one-off. Until then, the stock is a bet on a cycle that may have already peaked.